Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

Regulation of p53 stability by Mdm2

Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · see citing works

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

The p53-mdm-2 autoregulatory feedback loop.

Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · see citing works

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,447 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · see citing works

mdm2 expression is induced by wild type p53 activity.

Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290 · see citing works

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · see citing works

A Thioredoxin Gene Fusion Expression System That Circumvents Inclusion Body Formation in the E. coli Cytoplasm

LaVallie, E. R., DiBlasio-Smith, E. A., Kovacic, S., Grant, K. L., Schendel, P. F., & McCoy, J. M. (1993) · Nature Biotechnology · doi:10.1038/nbt0293-187 · Cited by 920 · see citing works

Differential induction of transcriptionally active p53 following UV or lonizing radiation: Defects in chromosome instability syndromes?

Lü, X. (1993) · Cell · doi:10.1016/0092-8674(93)90496-d · Cited by 772 · see citing works

In vivo ubiquitination and proteasome-mediated degradation of p53(1).

Maki, C. G., Huibregtse, J. M., & Howley, P. M. (1996) · PubMed · Cited by 645 · see citing works

High-frequency developmental abnormalities in p53-deficient mice

Armstrong, J. F., Kaufman, M. H., Harrison, D. J., & Clarke, A. R. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00183-7 · Cited by 466 · see citing works

Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2

Colas, P., Cohen, B. A., Jessen, T., Grishina, I. A., McCoy, J. M., & Brent, R. (1996) · Nature · doi:10.1038/380548a0 · Cited by 459 · see citing works

Small peptides activate the latent sequence-specific DNA binding function of p53

Hupp, T. R., Sparks, A., & Lane, D. P. (1995) · Cell · doi:10.1016/0092-8674(95)90165-5 · Cited by 433 · see citing works

Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene.

Juven‐Gershon, T., Barak, Y., Zauberman, A., George, D. L., & Oren, M. (1993) · PubMed · Cited by 332 · see citing works

The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.

Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311 · see citing works

Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.

Chen, C. Y., Oliner, J., Zhan, Q., Fornace, A. J., Vogelstein, B., & Kastan, M. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2684 · Cited by 270 · see citing works

Molecular characterization of the hdm2-p53 interaction 1 1Edited by J. Karn

Böttger, A., Böttger, V., Garcı́a-Echeverrı́a, C., Chêne, P., Hochkeppel, H. K., Sampson, W. R., Ang, K. H., Howard, S. F., Picksley, S. M., & Lane, D. P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1078 · Cited by 251 · see citing works

Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

Picksley, S. M., Vojtĕsek, B., Sparks, A., & Lane, D. P. (1994) · PubMed · Cited by 238 · see citing works

MDM2 Gene Amplification and Transcript Levels in Human Sarcomas: Relationship to TP53 Gene Status

Flørenes, V. A., Mælandsmo, G. M., Forus, A., Andreassen, Å. K., Myklebost, O., & Fodstad, Ø. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1297 · Cited by 188 · see citing works

Identification of novel mdm2 binding peptides by phage display.

Böttger, V., Böttger, A., Howard, S. F., Picksley, S. M., Chêne, P., Garcı́a-Echeverrı́a, C., Hochkeppel, H. K., & Lane, D. P. (1996) · PubMed · Cited by 182 · see citing works

Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.

Landers, J. E., Haines, D. S., STRAUSS, J. F., & George, D. L. (1994) · PubMed · Cited by 143 · see citing works

Regulation of p53 protein expression in human breast cancer cell lines

Vojtěšek, B., & Lane, D. P. (1993) · Journal of Cell Science · doi:10.1242/jcs.105.3.607 · Cited by 84 · see citing works

p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts.

Renzing, J., & Lane, D. P. (1995) · PubMed · Cited by 71 · see citing works

Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2

Blaydes, J. P., Gire, V., Rowson, J., & Wynford‐Thomas, D. (1997) · Oncogene · doi:10.1038/sj.onc.1201018 · Cited by 67 · see citing works

Similarities between prokaryotic and eukaryotic cyclic AMP-responsive promoter elements

Lin, Y.-S., & Green, M. R. (1989) · Nature · doi:10.1038/340656a0 · Cited by 41 · see citing works

Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53.

Otto, A., & Deppert, W. (1993) · PubMed · Cited by 41 · see citing works

Enhanced p53 activity and accumulation in response to DNA damage upon DNA transfection.

Siegel, J., Fritsche, M., Mai, S., Brandner, G., & Hess, R. D. (1995) · PubMed · Cited by 31 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

The RB and p53 pathways in cancer

Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · see citing works

Understanding protein non-folding

Uversky, V. N., & Dunker, A. K. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.01.017 · Cited by 1,188 · see citing works

The MDM2 gene amplification database

Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982 · see citing works

p53 and Human Cancer: The First Ten Thousand Mutations

Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 980 · see citing works

Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses

Rubbi, C. P., & Milner, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg579 · Cited by 811 · see citing works

The MDM2-p53 interaction.

Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 778 · see citing works

Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765 · see citing works

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 749 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage

Maya, R., Balass, M., Kim, S.-T., Shkedy, D., Leal, J.-F. M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., et al. (2001) · Genes & Development · doi:10.1101/gad.886901 · Cited by 716 · see citing works

Engineering novel binding proteins from nonimmunoglobulin domains

Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676 · see citing works

The unfoldomics decade: an update on intrinsically disordered proteins

Dunker, A. K., Oldfield, C. J., Meng, J., Romero, P. R., Yang, J. Y., Chen, J. W., Vacic, V., Zoran Obradovic, A., & Uversky, V. N. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-s2-s1 · Cited by 674 · see citing works

MDM2 — master regulator of the p53 tumor suppressor protein

Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641 · see citing works

SUMO‐1 modification activates the transcriptional response of p53

Rodríguez, M. S., Desterro, J. M. P., Laı́n, S., Midgley, C., Lane, D. P., & Hay, R. T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.22.6455 · Cited by 639 · see citing works

Drug discovery in the ubiquitin–proteasome system

Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 619 · see citing works

The cellular response to p53: the decision between life and death

Sionov, R. V., & Haupt, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1203130 · Cited by 600 · see citing works

Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study

Bar‐Or, R. L., Maya, R. B.-Y., Segel, L. A., Alon, U., Levine, A. J., & Oren, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210171597 · Cited by 579 · see citing works

Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity

Xirodimas, D. P., Saville, M. K., Bourdon, J.-C., Hay, R. T., & Lane, D. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.016 · Cited by 570 · see citing works

Regulation of the p53 Tumor Suppressor Protein

Oren, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36031 · Cited by 561 · see citing works

Molecular Interaction Map of the Mammalian Cell Cycle Control and DNA Repair Systems

Kohn, K. W. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.8.2703 · Cited by 550 · see citing works

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · see citing works

Evaluation of the use of therapeutic peptides for cancer treatment

Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 513 · see citing works

Modulators of Protein–Protein Interactions

Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497 · see citing works

Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2

Dumaz, N., & Meek, D. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.24.7002 · Cited by 455 · see citing works

Regulation of p53 function and stability by phosphorylation.

Ashcroft, M., Kubbutat, M. H. G., & Vousden, K. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1751 · Cited by 452 · see citing works

Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells

Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 433 · see citing works

Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity

Strano, S., Munarriz, E. R., Rossi, M., Castagnoli, L., Shaul, Y., Sacchi, A., Oren, M., Sudol, M., Cesareni, G., & Blandino, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010484200 · Cited by 418 · see citing works

Regulation of p53 stability

Ashcroft, M. A., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1203012 · Cited by 407 · see citing works

p300/MDM2 complexes participate in MDM2-mediated p53 degradation

Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414 · see citing works

Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation

Stommel, J. M., & Wahl, G. M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600145 · Cited by 386 · see citing works

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · see citing works

p53 and breast cancer, an update

Lacroix, M., Toillon, R., & Leclercq, G. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01172 · Cited by 380 · see citing works

Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2

Unger, T., Juven‐Gershon, T., Moallem, E., Berger, M., Sionov, R. V., Lozano, G., Oren, M., & Haupt, Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1805 · Cited by 365 · see citing works

Why target apoptosis in cancer treatment?

Kasibhatla, S., & Tseng, B. (2003) · PubMed · Cited by 351 · see citing works

The role of p53 in chemosensitivity and radiosensitivity

El‐Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206949 · Cited by 337 · see citing works

MDM2 suppresses p73 function without promoting p73 degradation

Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334 · see citing works

The p53 response to DNA damage

Meek, D. W. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.027 · Cited by 329 · see citing works

Activation and activities of the p53 tumour suppressor protein

Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 310 · see citing works

p53 stabilization is decreased upon NFκB activation

Tergaonkar, V., Pando, M. P., Vafa, O., Wahl, G. M., & Verma, I. M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00068-5 · Cited by 312 · see citing works

p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products

Yin, Y., Stephen, C. W., Luciani, M. G., & Fåhræus, R. (2002) · Nature Cell Biology · doi:10.1038/ncb801 · Cited by 305 · see citing works

Mechanisms of p53-mediated apoptosis

Bates, S., & Vousden, K. H. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050267 · Cited by 304 · see citing works

The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2

Stevenson, L. F., Sparks, A., Allende‐Vega, N., Xirodimas, D. P., Lane, D. P., & Saville, M. K. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601567 · Cited by 280 · see citing works

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo

Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256 · see citing works

An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo

Midgley, C., Desterro, J. M. P., Saville, M. K., Howard, S. F., Sparks, A., Hay, R. T., & Lane, D. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203593 · Cited by 250 · see citing works

Rational drug design via intrinsically disordered protein

Cheng, Y., LeGall, T., Oldfield, C. J., Mueller, J. P., Van, Y.-Y. J., Romero, P. R., Cortese, M. S., Uversky, V. N., & Dunker, A. K. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.07.005 · Cited by 248 · see citing works

p53-based Cancer TherapyPreprint

Lane, D. P., Cheok, C. F., & Laı́n, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 244 · see citing works

Excess β‐catenin promotes accumulation of transcriptionally active p53

Damalas, A., Ben‐Ze'ev, A., Simcha, I., Shtutman, M. S., Martínez-Leal, J. F., Zhurinsky, J., Geiger, B., & Oren, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.11.3054 · Cited by 238 · see citing works

<i>mdm2</i> Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation

Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.462-473.2003 · Cited by 234 · see citing works

Mechanisms of switching on p53: a role for covalent modification?

Meek, D. W. (1999) · Oncogene · doi:10.1038/sj.onc.1202951 · Cited by 235 · see citing works

Activation of p53 in cervical carcinoma cells by small molecules

Hietanen, S., Laı́n, S., Krausz, E., Blattner, C., & Lane, D. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8501 · Cited by 230 · see citing works

Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX

Hu, B., Gilkes, D. M., & Chen, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1140 · Cited by 214 · see citing works

Cyclin G Recruits PP2A to Dephosphorylate Mdm2

Okamoto, K., Li, H., Jensen, M. R., Zhang, T., Taya, Y., Thorgeirsson, S. S., & Prives, C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00504-x · Cited by 215 · see citing works

Transcription Factor E2F-1 Is Upregulated in Response to DNA Damage in a Manner Analogous to That of p53

Blattner, C., Sparks, A., & Lane, D. P. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3704 · Cited by 213 · see citing works

Mdm2 binds p73α without targeting degradation

Bálint, E., Bates, S., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202781 · Cited by 212 · see citing works

MdmX Protects p53 from Mdm2-Mediated Degradation

Jackson, M. W., & Berberich, S. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1001-1007.2000 · Cited by 211 · see citing works

Isolation of Protein Ligands from Large Peptoid Libraries

Alluri, P. G., Reddy, M. M., Bachhawat‐Sikder, K., Olivos, H. J., & Kodadek, T. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036417x · Cited by 210 · see citing works

Abundance of Intrinsic Disorder in Protein Associated with Cardiovascular Disease

Cheng, Y., LeGall, T., Oldfield, C. J., Dunker, A. K., & Uversky, V. N. (2006) · Biochemistry · doi:10.1021/bi060981d · Cited by 203 · see citing works

Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells

Hengstermann, A., Linares, L. K., Ciechanover, A. J., Whitaker, N. J., & Scheffner, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1218 · Cited by 212 · see citing works

Targeting the p53–MDM2 interaction to treat cancer

Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204 · see citing works

Mdm2: The Ups and Downs

Juven‐Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 193 · see citing works

Regulation of Mdm2-Directed Degradation by the C Terminus of p53

Kubbutat, M. H. G., Ludwig, R. L., Ashcroft, M. A., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5690 · Cited by 193 · see citing works

Comparative study of the p53-mdm2 and p53-MDMX interfaces

Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189 · see citing works

Identification of a cryptic nucleolar-localization signal in MDM2

Lohrum, M. A. E., Ashcroft, M. A., Kubbutat, M. H. G., & Vousden, K. H. (2000) · Nature Cell Biology · doi:10.1038/35004057 · Cited by 186 · see citing works

Targeting protein–protein interactions: Lessons from p53/MDM2

Murray, J. K., & Gellman, S. H. (2007) · Biopolymers · doi:10.1002/bip.20741 · Cited by 186 · see citing works

Using a β‐Hairpin To Mimic an α‐Helix: Cyclic Peptidomimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction

Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Vrijbloed, J. W., Obrecht, D., & Robinson, J. A. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200353242 · Cited by 183 · see citing works

Regulating the p53 system through ubiquitination

Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 179 · see citing works

p53 Activation by Small Molecules: Application in Oncology

Vassilev, L. T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058174k · Cited by 172 · see citing works

p53 and chemosensitivity

Ferreira, C. G., Tolis, C., & Giaccone, G. (1999) · Annals of Oncology · doi:10.1023/a:1008361818480 · Cited by 174 · see citing works

Dual-Site Regulation of MDM2 E3-Ubiquitin Ligase Activity

Wallace, M., Worrall, E. G., Pettersson, S., Hupp, T. R., & Ball, K. L. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.029 · Cited by 171 · see citing works

Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo

Xirodimas, D., Saville, M. K., Edling, C., Lane, D. P., & Laín, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204656 · Cited by 169 · see citing works

Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

Koblish, H. K., Zhao, S., Franks, C. F., Donatelli, R. R., Tominovich, R. M., LaFrance, L. V., Leonard, K. A., Gushue, J. M., Parks, D. J., Calvo, R. R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0199 · Cited by 164 · see citing works

Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo

Saville, M. K., Sparks, A., Xirodimas, D. P., Wardrop, J., Stevenson, L. F., Bourdon, J.-C., Woods, Y. L., & Lane, D. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403362200 · Cited by 158 · see citing works

DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation

Blattner, C., Tobiasch, E., Litfen, M., Rahmsdorf, H. J., & Herrlich, P. (1999) · Oncogene · doi:10.1038/sj.onc.1202480 · Cited by 151 · see citing works

Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2−Tumor Protein 53 Protein−Protein Interaction

Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R. W., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900681h · Cited by 148 · see citing works

Strategies for manipulating the p53 pathway in the treatment of human cancer

Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/bj3520001 · Cited by 148 · see citing works

Hypophosphorylation of Mdm2 Augments p53 Stability

Blattner, C., Hay, T., Meek, D. W., & Lane, D. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6170-6182.2002 · Cited by 144 · see citing works

Discovering novel chemotherapeutic drugs for the third millennium

Garrett, M. D., & Workman, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00280-4 · Cited by 141 · see citing works

Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D2concept

Uversky, V. N. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.36 · Cited by 141 · see citing works

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines 1 1Edited by A. R. Fersht

Chêne, P., Fuchs, J. P., Bohn, J. A., Garcı́a-Echeverrı́a, C., Furet, P., & Fabbro, D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3738 · Cited by 139 · see citing works

Understanding p53 functions through p53 antibodies

Sabapathy, K., & Lane, D. P. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz010 · Cited by 139 · see citing works

RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer

Fang, S., Lorick, K. L., Jensen, J. P., & Weissman, A. M. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00095-0 · Cited by 137 · see citing works

An Inhibitor of Nuclear Export Activates the p53 Response and Induces the Localization of HDM2 and p53 to U1A-Positive Nuclear Bodies Associated with the PODs

Laı́n, S., Midgley, C., Sparks, A., Lane, E. B., & Lane, D. P. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4433 · Cited by 135 · see citing works

The p53 protein family and radiation sensitivity: Yes or no?

Cuddihy, A. R., & Bristow, R. G. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031764.81141.e4 · Cited by 136 · see citing works

Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.

Chêne, P. (2004) · PubMed · Cited by 136 · see citing works

Covalent and noncovalent modifiers of the p53 protein

Jayaraman, L., & Prives, C. L. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050271 · Cited by 131 · see citing works

Molecular Basis for the Inhibition of p53 by Mdmx

Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 131 · see citing works

Inhibition of the p53-MDM2 Interaction: Targeting a Protein-Protein Interface

Chêne, P. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.20.2.1 · Cited by 152 · see citing works

Drugs Targeting Protein–Protein Interactions

Chêne, P. (2006) · ChemMedChem · doi:10.1002/cmdc.200600004 · Cited by 129 · see citing works

Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction

Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Obrecht, D., Mittl, P. R. E., Grütter, M. G., & Robinson, J. A. (2006) · ChemBioChem · doi:10.1002/cbic.200500452 · Cited by 129 · see citing works

The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation

Zilfou, J. T., Hoffman, W. H., Sank, M. J., George, D. L., & Murphy, M. E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3974-3985.2001 · Cited by 129 · see citing works

Cocompartmentalization of p53 and Mdm2 Is a Major Determinant for Mdm2-Mediated Degradation of p53

Xirodimas, D. P., Stephen, C. W., & Lane, D. P. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5314 · Cited by 127 · see citing works

Therapeutic exploitation of the p53 pathway

Lane, D. P., & Laı́n, S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02309-2 · Cited by 127 · see citing works

Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2

Maki, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16531 · Cited by 125 · see citing works

Phage-displayed peptide libraries

Zwick, M. B., Shen, J., & Scott, J. K. (1998) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(98)80017-7 · Cited by 126 · see citing works

Activation of the Cell Death Program by Nitric Oxide Involves Inhibition of the Proteasome

Glockzin, S., von Knethen, A., Scheffner, M., & Brüne, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.28.19581 · Cited by 123 · see citing works

Keeping an old friend under control: regulation of p53 stability

Kubbutat, M. H. G., & Vousden, K. H. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01260-x · Cited by 122 · see citing works

Activation of p53 by roscovitine-mediated suppression of MDM2 expression

Lu, W., Chen, L., Peng, Y., & Chen, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204412 · Cited by 117 · see citing works

The Conformationally Flexible S9–S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in Vivo

Shimizu, H., Burch, L. R., Smith, A. J., Dornan, D., Wallace, M., Ball, K. L., & Hupp, T. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202296200 · Cited by 116 · see citing works

p53—A Natural Cancer Killer: Structural Insights and Therapeutic Concepts

Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 115 · see citing works

Regulation of p53 stability by Mdm2

Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

MdmX Is Required for p53 Interaction with and Full Induction of the Mdm2 Promoter after Cellular Stress

Biderman, L., Poyurovsky, M. V., Assia, Y., Manley, J. L., & Prives, C. L. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06150-11 · Cited by 26 · see citing works

A New Twist in the Feedback Loop: Stress-Activated MDM2 Destabilization is Required for p53 Activation

Stommel, J. M., & Wahl, G. M. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1522 · Cited by 87 · see citing works

Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation

Kaku, S. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.1989 · Cited by 24 · see citing works